2024
Synaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse lossExamining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
Wang G, Li Y, Xiong C, Benzinger T, Gordon B, Hassenstab J, Aschenbrenner A, McDade E, Clifford D, Libre‐Guerra J, Shi X, Mummery C, van Dyck C, Lah J, Honig L, Day G, Ringman J, Brooks W, Fox N, Suzuki K, Levin J, Jucker M, Delmar P, Bittner T, Bateman R, Team F. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease. Alzheimer's & Dementia 2024 PMID: 38400532, DOI: 10.1002/alz.13735.Peer-Reviewed Original ResearchLatent classesPositron emission tomographyAmyloid reductionCognitive efficacyLatent class analysisAmyloid positron emission tomographyCognitive outcomesCognitive declineDominantly Inherited Alzheimer's Network Trials UnitSurrogate biomarkerBaseline characteristicsInherited Alzheimer's diseaseMultiple measuresClass analysisEmission tomographyTrials UnitAlzheimer's diseaseClinical trialsSurrogate endpointsTreatment effects
2009
Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET
Santhosh L, Estok KM, Vogel RS, Tamagnan GD, Baldwin RM, Mitsis EM, MacAvoy MG, Staley JK, van Dyck CH. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET. Psychiatry Research 2009, 173: 212-217. PMID: 19682865, DOI: 10.1016/j.pscychresns.2009.03.007.Peer-Reviewed Original ResearchConceptsPositron emission tomographyAD patient samplesAlzheimer's diseaseAD patientsAnterior cingulateBehavioral symptomsBrain serotonin 2A (5-HT(2A)) receptorsPatient samplesConstant infusion paradigmSerotonin 2A receptorProbable Alzheimer's diseaseMajor behavioral symptomsBehavioral correlatesInfusion paradigmPostmortem studiesPsychotic symptomsElderly controlsMRI scansSubcortical regionsSerotonergic dysregulationEmission tomographyPatientsDiseaseInterest analysisSymptoms
2001
The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans
Martinez D, Gelernter J, Abi-Dargham A, van Dyck C, Kegeles L, Innis R, Laruelle M. The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans. Neuropsychopharmacology 2001, 24: 553-560. PMID: 11282255, DOI: 10.1016/s0893-133x(00)00216-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmphetamineAttention Deficit Disorder with HyperactivityBenzamidesCarrier ProteinsCocaineCocaine-Related DisordersDopamineDopamine AntagonistsDopamine Plasma Membrane Transport ProteinsGenotypeHumansIodine RadioisotopesMembrane GlycoproteinsMembrane Transport ProteinsMinisatellite RepeatsNeostriatumNerve Tissue ProteinsPhenotypePolymorphism, GeneticPsychotic DisordersPyrrolidinesRadiopharmaceuticalsSchizophreniaTomography, Emission-Computed, Single-PhotonConceptsAmphetamine-induced dopamine releaseDopamine releaseDAT expressionDopamine transporterDifferent patient populationsAttention deficit hyperactivity disorderDeficit hyperactivity disorderNeurochemical phenotypePatient populationHealthy controlsDAT densityComputerized emission tomographyDopamine transmissionClinical phenotypeDiagnostic groupsSignificant associationEmission tomographyCocaine-induced paranoiaHyperactivity disorderTandem repeat polymorphismVNTR polymorphismDopamine transporter geneRepeat polymorphismTotal sampleReproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin
Soares J, van Dyck C, Tan P, Zoghbi S, Garg P, Soufer R, Baldwin R, Fujita M, Staley J, Fu X, Amici L, Seibyl J, Innis R. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Research 2001, 106: 81-93. PMID: 11306248, DOI: 10.1016/s0925-4927(01)00071-3.Peer-Reviewed Original ResearchConceptsTest/retest reproducibilityPositron emission tomographyCortical brain areasIntra-class correlation coefficientRetest reproducibilityBrain areasBrain measuresHealthy human subjectsMean intra-class correlation coefficientOutcome measuresConstant infusionParent tracerBlood measurementsEmission tomographyNeuropsychiatric disordersPET measuresReceptorsHuman subjectsPET acquisitionMean intraEquilibrium imagingImaging methodInfusionBolusRT